Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PROFILE: Bangladesh Market On Uptrend Amid Hep C Buildup

This article was originally published in PharmAsia News

Executive Summary

Half a dozen corporate players, community-based diagnosis and patient support efforts, and an inflow of treatment seekers from abroad keen to access cut-price drugs in the country – this probably summarizes the current state of play in Bangladesh's market for sofosbuvir.

You may also be interested in...



Bangladesh HCV Market: Can Generic Epclusa Shake Things Up?

Bangladesh's HCV market report card currently reads along these lines: generic versions of Sovaldi and Daklinza have made significant gains leaving interferon by the wayside, while generic Harvoni has had a quiet run. But, the arrival of cut-price Epclusa generics could bring change, besides putting the spotlight on the growing prowess of the South Asian nation's pharmaceutical industry.

Cyber-Attacked Dr Reddy’s Keeps Eye On Sputnik Plans

Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.

Cyberattacked Dr. Reddy’s Keeps Eye On Sputnik Plans

Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel